The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) is a huge mover today! About 422,348 shares traded hands or 98.20% up from the average. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 49.04% since April 27, 2016 and is downtrending. It has underperformed by 54.27% the S&P500.
The move comes after 8 months positive chart setup for the $153.40M company. It was reported on Nov, 30 by Barchart.com. We have $2.96 PT which if reached, will make NASDAQ:ABUS worth $6.14M more.
Analysts await Arbutus Biopharma Corp (NASDAQ:ABUS) to report earnings on March, 8. They expect $-0.35 EPS, down 212.90% or $0.66 from last year’s $0.31 per share. After $-0.31 actual EPS reported by Arbutus Biopharma Corp for the previous quarter, Wall Street now forecasts 12.90% negative EPS growth.
Arbutus Biopharma Corp (NASDAQ:ABUS) Ratings Coverage
Out of 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Arbutus Biopharma has been the topic of 11 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Chardan Capital Markets initiated Arbutus Biopharma Corp (NASDAQ:ABUS) rating on Monday, May 16. Chardan Capital Markets has “Sell” rating and $3.25 price target. RBC Capital Markets maintained it with “Outperform” rating and $20 target price in Friday, November 6 report. The stock has “Neutral” rating given by Chardan Capital Markets on Friday, October 14. The rating was initiated by Wedbush with “Outperform” on Friday, August 7. The firm has “Mkt Outperform” rating by JMP Securities given on Wednesday, September 2. The firm has “Sell” rating given on Friday, July 8 by Chardan Capital Markets. The firm has “Market Perform” rating given on Friday, August 5 by Leerink Swann. The stock has “Buy” rating given by Chardan Capital Markets on Wednesday, November 30. Wedbush initiated the shares of ABUS in a report on Friday, August 7 with “Outperform” rating. The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) has “Neutral” rating given on Thursday, June 16 by Chardan Capital Markets.
According to Zacks Investment Research, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.”
More important recent Arbutus Biopharma Corp (NASDAQ:ABUS) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on December 29, 2013, also Seekingalpha.com published article titled: “Arbutus Biopharma Corporation Is Poised To Catch Up In The Hepatitis B Race”, Globenewswire.com published: “Tekmira Announces Launch of Arbutus Biopharma, a Hepatitis B Solutions Company” on July 20, 2015. More interesting news about Arbutus Biopharma Corp (NASDAQ:ABUS) was released by: Quotes.Wsj.com and their article: “News Arbutus Biopharma Corp.ABUS” with publication date: August 06, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.